Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma

Cancer Biomarkers

Volumn 10, Issue 2, 2011, Pages 101-107

  Chung, Kyukwang ^a   Nishiyama, Noritoshi ^a   Yamano, Shotaro ^a   Komatsu, Hiroaki ^a   Hanada, Shoji ^a   Wei, Min ^a   Wanibuchi, Hideki ^a   Suehiro, Shigefumi ^a   Kakehashi, Anna ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

AGR2; early detection; lung adenocarcinoma; prognosis; serum biomarker

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEINS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

XENOPUS LAEVIS;

EID: 84859351905     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2012-0234     Document Type: Article

References (31)

1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, M.J. Thun, Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66. (Pubitemid 46148091)
2. T. Naruke, R. Tsuchiya, H. Kondo, H. Asamura, Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 71 (2001) 1759-1764. (Pubitemid 32554394)
3. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu, D.H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98. (Pubitemid 34438899)
4. D.M. Parkin, Global cancer statistics in the year 2000. Lancet Oncol 2 (2001) 533-543. (Pubitemid 33586866)
5. S. Singhal, A. Vachani, D. Antin-Ozerkis, L.R. Kaiser, S.M. Albelda, Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 11 (2005) 3974-3986. (Pubitemid 40791561)
6. K. Matsuoka, S. Sumitomo, N. Nakashima, D. Nakajima, N. Misaki, Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Eur J Cardiothorac Surg 32 (2007) 435-439. (Pubitemid 47223713)
7. D.A. Thompson, R.J. Weigel, hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem Biophys Res Commun 251 (1998) 111-116. (Pubitemid 28498072)
8. T. Komiya, Y. Tanigawa, S. Hirohashi, Cloning of the gene gob-4, which is expressed in intestinal goblet cells in mice. Biochim Biophys Acta 1444 (1999) 434-438. (Pubitemid 29147317)
9. S.F.Altschul, T.L.Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, D.J. Lipman, Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25 (1997) 3389-3402. (Pubitemid 27359211)
10. S. Persson, M. Rosenquist, B. Knoblach, R. Khosravi-Far, M. Sommarin, M. Michalak, Diversity of the protein disul- fide isomerase family: identification of breast tumor induced Hag2 and Hag3 as novel members of the protein family. Mol Phylogenet Evol 36 (2005) 734-740. (Pubitemid 41138906)
11. H.E. Innes, D. Liu, R. Barraclough, M.P.Davies, P.A.O'Neill, A. Platt-Higgins, S. de Silva Rudland, D.R. Sibson, P.S. Rudland, Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 94 (2006) 1057-1065.
12. D.L. Barraclough, A. Platt-Higgins, S. de Silva Rudland, R. Barraclough, J. Winstanley, C.R. West, P.S. Rudland, The metastasis-associated anterior gradient 2 protein is correlated with poor survival of breast cancer patients. Am J Pathol 175 (2009) 1848-1857.
13. T.A. Edgell, D.L. Barraclough, A. Rajic, J. Dhulia, K.J. Lewis, J.E. Armes, R. Barraclough, P.S. Rudland, G.E. Rice, D.J. Autelitano, Increased plasma concentrations of anterior gradient 2 protein are positively associated with ovarian cancer. Clin Sci (Lond) 118 (2010) 717-725.
14. M. Groome, J. Lindsay, P.E. Ross, J.P. Cotton, T.R. Hupp, J.F. Dillon, Use of oesophageal stress response proteins as potential biomarkers in the screening for Barrett's oesophagus. Eur J Gastroenterol Hepatol 20 (2008) 961-965.
15. E. Pohler, A.L. Craig, J. Cotton, L. Lawrie, J.F. Dillon, P. Ross, N. Kernohan, T.R. Hupp, The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol Cell Proteomics 3 (2004) 534-547. (Pubitemid 38878513)
16. V. Ramachandran, T. Arumugam, H. Wang, C.D. Logsdon, Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res 68 (2008) 7811-7818.
17. R. Chen, S. Pan, X. Duan, B.H. Nelson, R.A. Sahota, S. de Rham, R.A. Kozarek, M. McIntosh, T.A. Brentnall, Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol Cancer 9 (2010) 149.
18. Y. Zhang, S.S. Forootan, D. Liu, R. Barraclough, C.S. Foster, P.S. Rudland, Y. Ke, Increased expression of anterior gradient- 2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 10 (2007) 293-300. (Pubitemid 47351409)
19. F.R. Fritzsche, E. Dahl, A. Dankof, M. Burkhardt, S. Pahl, I. Petersen, M. Dietel, G. Kristiansen, Expression of AGR2 in non small cell lung cancer. Histol Histopathol 22 (2007) 703-708. (Pubitemid 47034136)
20. Z.Wang, Y. Hao, A.W. Lowe, The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 68 (2008) 492-497. (Pubitemid 351380076)
21. D. Liu, P.S. Rudland, D.R. Sibson, A. Platt-Higgins, R. Barraclough, Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. Cancer Res 65 (2005) 3796-3805. (Pubitemid 40616358)
22. A. Dong, A. Gupta, R.K. Pai, M. Tun, A.W. Lowe, The Human Adenocarcinoma-associated Gene, AGR2, Induces Expression of Amphiregulin through Hippo Pathway Co-activator YAP1 Activation. J Biol Chem 286 (2011) 18301-18310.
23. W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato, E. Brambilla, (Eds.) Histological Typing of Lung and Pleural Tumors: World Health Organization International Histological Classification of Tumors, 3rd edn., Springer, Berlin, 1999.
24. L. Sobin, C.H. Wittekind, (Eds.) TMN Classification of Malignant Tumours, 6th ed., Wiley-Liss, New York, 2002.
25. W.C. Cho, T.T. Yip, W.W. Cheng, J.S. Au, Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer 102 (2010) 1731-1735.
26. W.C. Cho, Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 61 (2007) 515-519.
27. D.A. Smirnov, D.R. Zweitzig, B.W. Foulk, M.C. Miller, G.V. Doyle, K.J. Pienta, N.J. Meropol, L.M. Weiner, S.J. Cohen, J.G. Moreno, M.C. Connelly, L.W. Terstappen, S.M. O'Hara, Global gene expression profiling of circulating tumor cells. Cancer Res 65 (2005) 4993-4997. (Pubitemid 40827303)
28. M. Valladares-Ayerbes, S. Diaz-Prado, M. Reboredo, V. Medina, P. Iglesias-Diaz, M.J. Lorenzo-Patino, R.G. Campelo, M. Haz, I. Santamarina, L.M. Anton-Aparicio, Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect Prev 32 (2008) 236-250.
29. R. Hrstka, R. Nenutil, A. Fourtouna, M.M. Maslon, C. Naughton, S. Langdon, E. Murray, A. Larionov, K. Petrakova, P. Muller, M.J. Dixon, T.R. Hupp, B. Vojtesek, The prometastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene 29 (2010) 4838-4847.
30. L. Zhao, B.Y. Lee, D.A. Brown, M.P. Molloy, G.M. Marx, N. Pavlakis, M.J. Boyer, M.R. Stockler, W. Kaplan, S.N. Breit, R.L. Sutherland, S.M. Henshall, L.G. Horvath, Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 69 (2009) 7696-7703.
31. L. Dumartin, H.J. Whiteman, M.E. Weeks, D. Hariharan, B. Dmitrovic, C.A. Iacobuzio-Donahue, T.A. Brentnall, M.P. Bronner, R.M. Feakins, J.F. Timms, C. Brennan, N.R. Lemoine, T. Crnogorac-Jurcevic, AGR2 Is a Novel Surface Antigen That Promotes the Dissemination of Pancreatic Cancer Cells through Regulation of Cathepsins B and D. Cancer Res 71 (2011) 7091-7102.